Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker. In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD). In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.
References
